Ozempic and Gastroparesis: Understanding Symptoms and the Path to Diagnosis

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Targeted Risk Assessment

If you're experiencing persistent nausea, vomiting, or abdominal pain after starting Ozempic, you may be wondering if it's related to gastroparesis. The medical community has long recognized that certain medications can affect gastric motility, and recent attention has focused on GLP-1 receptor agonists. This page explains the typical symptoms of Ozempic-associated gastroparesis and outlines the steps involved in reaching a diagnosis.

Understanding Ozempic and Its Gastrointestinal Effects

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for chronic weight management. Among its known adverse effects, gastrointestinal (GI) reactions are prominent and have been documented in clinical trials. In placebo-controlled studies, GI adverse reactions occurred more frequently in patients receiving Ozempic than placebo: 32.7% with Ozempic 0.5 mg, 36.4% with Ozempic 1 mg, and 34.0% with Ozempic 2 mg, compared to 15.3% with placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and diarrhea occurred during dose escalation, and discontinuation due to GI adverse reactions was higher with Ozempic (3.1% for 0.5 mg, 3.8% for 1 mg) than placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional GI reactions with a frequency below 5% included dyspepsia (1.9% placebo, 3.5% Ozempic 0.5 mg, 2.7% Ozempic 1 mg), gastroesophageal reflux disease (0% placebo, 1.9% Ozempic 0.5 mg, 1.5% Ozempic 1 mg), and gastritis (0.8% placebo, 0.8% Ozempic 0.5 mg, 0.4% Ozempic 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Gastroparesis: A Potential Consequence of GLP-1 Agonist Use

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical presentation can vary from mild discomfort to severe malnutrition and dehydration. Diagnosis typically involves gastric emptying scintigraphy or breath tests. The mechanistic link between GLP-1 receptor agonists like Ozempic and gastroparesis is biologically plausible. GLP-1 receptors are expressed in the gastrointestinal tract and central nervous system, and their activation slows gastric motility and emptying. This pharmacodynamic effect is intended to promote satiety and reduce postprandial glucose excursions but can become pathological when exaggerated or sustained. In susceptible individuals, chronic use of Ozempic may induce or exacerbate gastroparesis by impairing antral contractions and pyloric relaxation, leading to functional gastric outlet delay. While the prescribing information does not explicitly list gastroparesis as a labeled adverse reaction, the reported GI adverse events—including dyspepsia, gastroesophageal reflux disease, and gastritis—overlap with symptoms of gastroparesis and may reflect underlying motility disturbances (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Legal and Settlement Considerations for Ozempic-Related Gastroparesis

From a risk perspective, the adequacy of warnings regarding Ozempic and gastroparesis is a central consideration. The current label warns of serious hypersensitivity reactions, including anaphylaxis and angioedema, and advises caution in patients with a history of such reactions to other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, it does not specifically warn about the risk of gastroparesis or delayed gastric emptying as a distinct adverse effect. This omission may be relevant for patients who develop severe, persistent GI symptoms that meet diagnostic criteria for gastroparesis. For affected patients, settlement-related considerations hinge on demonstrating a causal link between Ozempic exposure and the development of gastroparesis, as well as the adequacy of informed consent. Key factors include the timeline between exposure and documented harm: GI adverse reactions are most common during dose escalation, but gastroparesis may develop insidiously over weeks to months of treatment. Patients who experienced worsening symptoms after dose increases or prolonged use may have stronger claims. Additionally, the severity of harm—such as hospitalization, nutritional deficiencies, or need for interventions like gastric pacing or feeding tubes—can influence settlement criteria. In summary, the evidence indicates that Ozempic is associated with a range of GI adverse reactions, including those that overlap with gastroparesis symptoms. The mechanistic pathway involving GLP-1 receptor-mediated gastric slowing supports a plausible link. However, the label does not explicitly warn about gastroparesis, which may affect risk assessment for affected patients. Settlement considerations will likely require careful documentation of symptom onset, diagnostic confirmation, and temporal association with Ozempic use.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric motility as part of its mechanism. In susceptible individuals, chronic use may induce or exacerbate gastroparesis, a condition of delayed gastric emptying. Clinical trials show higher rates of GI adverse events like nausea, vomiting, and dyspepsia with Ozempic compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What are the settlement criteria for Ozempic gastroparesis lawsuits?

Settlement criteria typically require documented Ozempic exposure, a confirmed gastroparesis diagnosis via gastric emptying scintigraphy or breath tests, a temporal association between use and symptom onset, and evidence of inadequate warnings. Severity of harm, such as hospitalization or need for interventions, may also influence eligibility.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.